Dr. Richard Channick Addresses a New Treatment in Pulmonary Arterial Hypertension
In this video, Richard Channick, MD, Director, Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Boston, MA, speaks about the use of Macitentan for the treatment of pulmonary arterial hypertension (PAH). Dr Channick says that Macitentan, compared to placebo, significantly improved morbidity in PAH. The results demonstrated in the SERAPHIN clinical trial also proved that Macitentan decreased hospitalizations in patients with PAH.
This video was taken on May 20, 2013, at the ATS 2013 International Conference in Philadelphia, PA.
The Republican-led House of Representatives voted on Wednesday to delay for one year the tax penalty Americans will pay under President Barack Obama's healthcare law if they decline to enroll in health coverage for this year.
For state exchanges still struggling to function, and governors facing the consequences, the Centers for Medicare & Medicaid Services is offering an exception to the rule of tax credits only being available through public marketplaces.
The American Academy of Allergy, Asthma & Immunology (AAAAI) on Monday released its second list of overused tests and procedures that allergists, primary care physicians, and patients should question before they occur. The list represents the fruits of the Academy’s second year of participation in the “Choosing Wisely” initiative, and was presented at a press conference during the Academy’s meeting in San Diego, California.
It’s one of the most impressive statistics about the new health care law. The Obama administration says more than 8.9 million people have been, quote “determined eligible” for Medicaid from Oct. 1 through the end of January.